Redx Pharma plc Holdings in Company (8621S)

TIDMREDX

RNS Number : 8621S

Redx Pharma plc

09 November 2023

REDX PHARMA PLC

("Redx" or the "Company")

Holdings in Company

Alderley Park, UK, 9 November 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer, announces the following changes to its significant shareholders (being shareholders holding 3% or more of the Company's ordinary shares) pursuant to AIM Rule 17, following admission of the Subscription Shares to trading on AIM (as announced on 7 November 2023) and as detailed further in the circular to shareholders dated 18 October 2023.

 
 Shareholder                 Number of ordinary   Percentage of issued 
                                         shares          share capital 
 Funds managed by Redmile 
  Group LLC                         276,890,319                  71.18 
                            -------------------  --------------------- 
 Sofinnova Crossover 
  I SLP                              51,948,307                  13.35 
                            -------------------  --------------------- 
 Polar Capital LLP                   24,321,504                   6.25 
                            -------------------  --------------------- 
 Invus Public Equities 
  L.P.                               15,203,815                   3.91 
                            -------------------  --------------------- 
 
 
For further information, please contact: 
 
Redx Pharma plc                                             T: [phone] 
 Caitlin Pearson, Head of Communications [e-mail]   918 
 UK Headquarters 
 Lisa Anson, Chief Executive Officer 
US Office 
 Peter Collum, Chief Financial Officer 
 
SPARK Advisory Partners (Nominated Adviser)                 T: [phone] 
                                                             3550 
Matt Davis/ Adam Dawes 
 
  WG Partners LLP (Joint Broker)                              T: [phone] 
                                                              9330 
Claes Spång/ Satheesh Nadarajah/ David 
 Wilson 
 
  Panmure Gordon (UK) Limited (Joint Broker)                  T: [phone] 
                                                              2500 
Rupert Dearden/ Freddy Crossley/ Emma Earl 
FTI Consulting                                              T: [phone] 
                                                             1000 
Simon Conway/ Ciara Martin 
 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA application during the fourth quarter of 2023. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development. In October 2023, Redx nominated its next development candidate, RXC009 a highly potent and selective DDR1 inhibitor for the treatment of chronic kidney disease and associated fibrosis.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/ .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLFFFSILILTIIV

(END) Dow Jones Newswires

November 09, 2023 02:00 ET (07:00 GMT)